FDA药品监管参考检索页:涵盖药品质量、临床试验与生物制品指南
Search for Regulatory References | Drugs
美国FDA药品与生物制品信息页面提供监管参考检索入口,汇集药品质量与生产、供应链、临床试验与药物开发审批、生物制品与生物类似药等主题的指南快照及配套播客文字记录。页面还收录仿制药、OTC专论、生物标志物资格认定等栏目,供检索相关法规、法律与指南文件。
Supply ChainDrug Supply ChainSearch for Pharmaceutical Quality DocumentsPharmaceutical Quality and ManufacturingMultiple Endpoints Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalEthical Considerations for Clinical Investigations Involving Children -Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalNeonatal Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPatient-Focused Drug Development Clinical Outcome Assessments
Guidance
SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalFood Effects Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalBioavailability Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPopulation Pharmacokinetics Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPathology Peer Review Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalBenefit-Risk Assessment for New Drug and Biologic Products SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalAdjusting for Covariates Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalIn Vitro Drug Interaction Studies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalClinical Drug Interaction Studies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalComplex Innovative Trial Designs Guidance SnapshotRegulations, Laws, Guidances; Meetings, Engaging with FDAMaximal Usage Trials Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalTargeted Therapies Guidance SnapshotRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalMultiple Endpoints Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalEthical Considerations for Clinical Investigations Involving Children -Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalNeonatal Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPatient-Focused Drug Development Clinical Outcome Assessments
Guidance Recap
Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalFood Effects Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalBioavailability Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPopulation Pharmacokinetics Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalPathology Peer Review Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalAdjusting for Covariates Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalIn Vitro Drug Interaction Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalClinical Drug Interaction Studies Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Clinical Trials, Drug Development and ApprovalComplex Innovative Trial Designs Guidance Recap Podcast TranscriptRegulations, Laws, Guidances; Meetings, Engaging with FDAComplex Generics NewsGeneric Drugs, Abbreviated New Drug ApplicationsEmerging Technology ProgramPharmaceutical Quality and ManufacturingOncology Regulatory Expertise and Early Guidance (OREEG)Clinical Trials, Drug Development and Approval, Investigational New Drug Development Application (IND), Meetings, Engaging with FDAOTC Monographs@FDAOver-the-Counter Drug ReviewOver-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES ActOver-the-Counter Drug ReviewPhonetic and Orthographic Computer Analysis (POCA) ProgramDrug Safety; Clinical Trials, Drug Development and ApprovalAbout CDER Small Business and Industry AssistanceAbout FDA and CDERAbout FDAAbout FDA and CDERCDER Exclusivity BoardAbout FDA and CDERCDER OmbudsmanAbout FDA and CDERDoing Business With FDAAbout FDA and CDERJobs at FDAAbout FDA and CDERBiosimilar Development, Review, and ApprovalBiologics, Biosimilars, Biologics License Application (BLA) Biosimilar Product Information (FDA-Approved List of Biological Products)Biologics, Biosimilars, Biologics License Application (BLA) BiosimilarsBiologics, Biosimilars, Biologics License Application (BLA) Biosimilars Action PlanBiologics, Biosimilars, Biologics License Application (BLA) Bisoimilar Industry Information and GuidanceBiologics, Biosimilars, Biologics License Application (BLA) "Deemed to be a License Provision" of the BPCI ActBiologics, Biosimilars, Biologics License Application (BLA) Frequently Asked Questions About Therapeutic Biological ProductsBiologics, Biosimilars, Biologics License Application (BLA) Therapeutic Biologic Applications (BLA) Approval InformationBiologics, Biosimilars, Biologics License Application (BLA) Transfer of Therapeutic Products to CDER Biologics, Biosimilars, Biologics License Application (BLA) Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability EvaluationsBiologics, Biosimilars, Biologics License Application (BLA); DatabasesBiosimilar User Fee Amendments (BsUFA)Biologics, Biosimilars, Biologics License Application (BLA); User FeesBiomarker Qualification ProgramClinical Trials, Drug Development and ApprovalCombination Products Clinical Trials, Drug Development and ApprovalClinical Trials and Human Subject ProtectionClinical Trials, Drug Development and ApprovalDevelopment & Approval ProcessClinical Trials, Drug Development and ApprovalDrug Development and Drug Interactions: Table of Substrates, Inhibitors and InducersClinical Trials, Drug Development and ApprovalDrug Development ProcessClinical Trials, Drug Development and ApprovalThe FDA's Drug Review Process: Ensuring Drugs Are Safe and EffectiveClinical Trials, Drug Development and ApprovalEconomic Assistance and Incentives for Drug DevelopmentClinical Trials, Drug Development and ApprovalCoronavirus (COVID-19)Clinical Trials, Drug Development and ApprovalCOVID MyStudies Application (App)Clinical Trials, Drug Development and ApprovalFrequently Asked Questions on Patents and ExclusivityClinical Trials, Drug Development and ApprovalReal-World EvidenceClinical Trials, Drug Development and ApprovalCompliance Actions and ActivitiesCompliance, Inspections, EnforcementInspections, Compliance, Enforcement, and Criminal InvestigationsCompliance, Inspections, EnforcementUnapproved DrugsCompliance, Inspections, EnforcementWarning Letters and Notice of Violation Letters to Pharmaceutical CompaniesCompliance, Inspections, EnforcementCompounding and the FDA: Questions and AnswersCompoundingCompounding Risk AlertsCompoundingCompounding: Inspections, Recalls, and other ActionsCompoundingHuman Drug CompoundingCompoundingDrug Approvals and DatabasesDatabasesDrugs@FDADatabasesFDALabelDatabasesInactive Ingredient DatabaseDatabasesNational Drug Code DirectoryDatabasesDrug ShortagesDatabasesSearch List of Extended Use Dates to Assist with Drug ShortagesDatabasesApproved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)Databases; Generic Drugs, Abbreviated New Drug Application (ANDA)Drug Master File webpageDrug Master FilesDrug Master Files: GuidelinesDrug Master FilesType II DMFs for Active Pharmaceutical IngredientsDrug Master FilesTypes of Drug Master Files (DMFs)Drug Master FilesDrug RecallsDrug Safety, RecallsDrug Safety CommunicationsDrug Safety, RecallsFDA Adverse Event Reporting System (FAERS) Public DashboardDrug Safety, RecallsMedwatchDrug Safety, RecallsPreventable Adverse Drug Reactions: A Focus on Drug InteractionsDrug Safety, RecallsRisk Evaluation and Mitigation Strategies (REMS)Drug Safety, RecallsDrug Safety Labeling ChangesDrug Safety, Recalls; LabelingFDA Adverse Event Reporting System (FAERS) Electronic SubmissionsDrug Safety, Recalls; Submissions, Forms, ContactsMedwatch Reporting for IndustryDrug Safety, Recalls; Submissions, Forms, ContactsDrug Safety and AvailabilityDrug Safety; DatabasesDrug Supply Chain IntegrityDrug Supply ChainDrug Supply Chain Security ActDrug Supply ChainVerify Wholesale Drug Distributor LicensesDrug Supply ChainAbbreviated New Drug Application (ANDA)Generic Drugs, Abbreviated New Drug Application (ANDA)Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for IndustryGeneric Drugs, Abbreviated New Drug Application (ANDA)Dissolution Methods DatabaseGeneric Drugs, Abbreviated New Drug Application (ANDA)First Generic Drug ApprovalsGeneric Drugs, Abbreviated New Drug Application (ANDA)Generic Drug Research-Related Guidances and ReportsGeneric Drugs, Abbreviated New Drug Application (ANDA)Generic Drugs: Information for IndustryGeneric Drugs, Abbreviated New Drug Application (ANDA)Guidance Documents for Generic Drugs (search Generics under topic)Generic Drugs, Abbreviated New Drug Application (ANDA)Guidance for Industry: ANDA Submission - Content and Format of ANDAsGeneric Drugs, Abbreviated New Drug Application (ANDA)Orange Book PrefaceGeneric Drugs, Abbreviated New Drug Application (ANDA)Patent Certifications and Suitability PetitionsGeneric Drugs, Abbreviated New Drug Application (ANDA)Product-Specific Guidances for Generic Drug DevelopmentGeneric Drugs, Abbreviated New Drug Application (ANDA)Self-Identification of Generic Drug Facilities, Sites and OrganizationsGeneric Drugs, Abbreviated New Drug Application (ANDA)Pre-ANDA ProgramGeneric Drugs, Abbreviated New Drug Application (ANDA); Meetings, Engaging with FDAFDA List of Authorized Generic DrugsGeneric Drugs, Abbreviated New Drug Application (ANDA); New Drug Review, New Drug Application (NDA)ANDA Forms and Submissions RequirementsGeneric Drugs, Abbreviated New Drug Application (ANDA); Submissions, Forms, ContactsControlled CorrespondenceGeneric Drugs, Abbreviated New Drug Application (ANDA); Submissions, Forms, ContactsGDUFA web-based learning coursesGeneric Drugs, Abbreviated New Drug Application (ANDA); User FeesGeneric Drug User Fee Amendments (GDUFA)Generic Drugs, Abbreviated New Drug Application (ANDA); User FeesExport certificatesImport/Export, Regulatory Affairs, International ProgramsInformation for ExportersImport/Export, Regulatory Affairs, International ProgramsOffice of Global Policy and StrategyImport/Export, Regulatory Affairs, International ProgramsOffice of Regulatory Affairs (ORA) Directory Import/Export, Regulatory Affairs, International Programs; Submissions, Forms, ContactsExpanded Access: Information for IndustryInvestigational New Drug Application (IND)Expedited ProgramsInvestigational New Drug Application (IND)Exploratory INDsInvestigational New Drug Application (IND)IND ExemptionsInvestigational New Drug Application (IND)Investigational New Drug (IND) ApplicationInvestigational New Drug Application (IND)Investigator-Initiated INDs and IND submission proceduresInvestigational New Drug Application (IND)Pregnancy and Lactation Labeling (Drugs) Final RuleLabelingFDA’s Labeling Resources for Human Prescription DrugsLabelingTable of Pharmacogenomic Biomarkers in Drug LabelingLabelingMedication GuidesLabeling; DatabasesAdvisory Committees (human drugs)Meetings, Engaging with FDABest Practices for Communication Between IND Sponsors and FDA During Drug DevelopmentMeetings, Engaging with FDAEngaging with FDA during New Drug Development CDERLearn CourseMeetings, Engaging with FDANews & Events for Human DrugsMeetings, Engaging with FDA; About FDA and CDERFormal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for IndustryMeetings, Engaging with FDA; Generic Drugs, Abbreviated New Drug Application (ANDA)Pre-IND Meeting FAQs Meetings, Engaging with FDA; Investigational New Drug Application (IND)Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for IndustryMeetings, Engaging with FDA;
Biologics, Biosimilars, Biologics License Application (BLA) Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Meetings, Engaging with FDA;
Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA)New Drug Application (NDA) ResourcesNew Drug Review, New Drug Application (NDA)Requesting a Pre-Assigned Application numberNew Drug Review, New Drug Application (NDA)Applications Covered by Section 505(b)2) Guidance for IndustryNew Drug Review, New Drug Application (NDA); Investigational New Drug Application (IND)Prescription Drug User Fee Amendments (PDUFA)New Drug Review, New Drug Application (NDA); User FeesUser Fee Waivers, Reduction, and Refunds for Drug and Biological Products - Guidance for IndustryNew Drug Review, New Drug Application (NDA); User FeesDevelopment and Regulation of OTC (Nonprescription) DrugsOver-the-Counter Drug ReviewDrug applications for OTC drugsOver-the-Counter Drug ReviewOTC Monographs and RulemakingOver-the-Counter Drug ReviewOver-the-Counter (OTC) Drug Monograph ProcessOver-the-Counter Drug ReviewOver-the-Counter Monograph User Fee Program (OMUFA)Over-the-Counter Drug Review; User FeesCurrent Good Manufacturing Practice (CGMP) RegulationsPharmaceutical Quality and ManufacturingDrug Quality Sampling and Testing ProgramsPharmaceutical Quality and ManufacturingExpiration Dates - Questions and AnswersPharmaceutical Quality and ManufacturingFacts About CGMPsPharmaceutical Quality and ManufacturingPharmaceutical Quality Resources Pharmaceutical Quality and ManufacturingQuality Metrics for Drug ManufacturingPharmaceutical Quality and ManufacturingQuestions and Answers on CGMPsPharmaceutical Quality and ManufacturingQuestions and Answers on Current Good Manufacturing Practices—Control of Components and Drug Product Containers and ClosuresPharmaceutical Quality and ManufacturingQuestions and Answers on Current Good Manufacturing Practices—Production and Process ControlsPharmaceutical Quality and ManufacturingReport a Product Quality IssuePharmaceutical Quality and ManufacturingCurrent Good Manufacturing Practice (CGMP) RegulationsPharmaceutical Quality and Manufacturing; Regulations, Laws, GuidancesOffice of Prescription Drug Promotion (OPDP)Post-Marketing Activities and PromotionTruthful Prescription Drug Advertising and Promotion (Bad Ad Program)Post-Marketing Activities and PromotionPostmarket Drug Safety Information for Patients and ProvidersPost-Marketing Activities and Promotion; Drug SafetyPostmarketing Surveillance ProgramsPost-Marketing Activities and Promotion; Drug SafetyDeveloping Products for Rare Diseases and ConditionsRare Diseases and Orphan DrugsFrequently Asked Questions (FAQ) About Designating an Orphan ProductRare Diseases and Orphan DrugsSearch Orphan Drug Designations and ApprovalsRare Diseases and Orphan DrugsCDER Direct: Electronic Submissions PortalRegistration and ListingElectronic Drug Registration and Listing InstructionsRegistration and ListingDrug Establishments Current Registration Site (DECRS Database)Registration and Listing; DatabasesRegistered Outsourcing Facilities (Compounding)Registration and Listing; DatabasesCode of Federal Regulations, Title 21Regulations, Laws, GuidancesFederal Food Drug & Cosmetic ActRegulations, Laws, GuidancesLaws, Regulations and GuidancesRegulations, Laws, GuidancesSearch for FDA Guidance DocumentsRegulations, Laws, GuidancesCDER Reports & BudgetReportsDivision of Applied Regulatory Science Annual ReportsReportsDrug and Biologic Approval and IND Activity ReportsReportsFast Track ApprovalsReportsGDUFA Science and Research ReportsReportsIND Application Reporting: Safety ReportsReportsNDA and BLA ApprovalsReportsNDA and BLA Calendar Year ApprovalsReportsOffice of Clinical Pharmacology Annual ReportsReportsOffice of Generic Drugs Annual ReportsReportsOffice of New Drugs Annual ReportsReportsOffice of Pharmaceutical Quality Annual ReportsReportsCDER Data Standards ProgramSubmissions, Forms, ContactsCDER Direct NextGen Collaboration PortalSubmissions, Forms, ContactsCDER Direct NextGen Collaboration Portal FAQsSubmissions, Forms, ContactsElectronic Regulatory Submission and ReviewSubmissions, Forms, ContactsFDA FormsSubmissions, Forms, ContactsForms and Submission RequirementsSubmissions, Forms, ContactsOffice of New Drugs ContactsSubmissions, Forms, ContactsAddresses for regulatory submissionsSubmissions, Forms, Contacts; Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA); Generic Drugs, Abbreviated New Drug Application (ANDA)Electronic Common Technical Document (eCTD)Submissions, Forms, Contacts; Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA); Generic Drugs, Abbreviated New Drug Application (ANDA)FDA IND, NDA, ANDA, or Drug Master File BindersSubmissions, Forms, Contacts; Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA); Generic Drugs, Abbreviated New Drug Application (ANDA); Drug Master FilesCDER SBIA Learn: Respository of Training Resources and RecordingsTraining ResourcesCDERLearn Training and EducationTraining ResourcesStay Informed with FDA Interactive MediaTraining ResourcesVideo and Transcript: FDA/CDER's Small Business and Industry Assistance (SBIA)Training ResourcesFDA User Fee ProgramsUser Fees
来源:FDA 官方药品与生物制品信息 · fda.gov